Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
ACQUIRED COMPANY
 
My Lists

Kai Pharmaceuticals  Acquired by Amgen (2012 $ 315,000,000 )

270 Littlefield Avenue
South San Francisco, CA 94080
USA
(650)-244-1100
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Daria Mochly-Rosen (Kai Pharmaceuticals Professor) Sigrid Van Bladel (NEA Former Partner) Paul Sekhri (Cerimon Pharmaceuticals Former President/CEO) Stephen J. Hoffman (Skyline Ventures Managing Director) Abhijeet J. Lele (Investor Growth Capital Managing Director) Chris Ehrlich (InterWest Partners Partner)
Company

Business description: KAI is a clinical-stage, biopharmaceutical company whose lead peptide product candidate, KAI-4169, is in development for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is characterized by an elevation of parathyroid hormone also referred to as secondary hyperparathyroidism. (SHPT). Building on promising, early-stage clinical data, KAI has advanced KAI-4169 into Phase 2 clinical development in end-stage renal disease (ESRD) patients on dialysis, which is expected to complete in the second half of 2011. In addition, preclinical research is being conducted on pre-hemodialysis applications of KAI-4169. KAI’s leadership team has a strong background and track record in successful product development and commercialization. The Company is backed by a leading syndicate of venture investors, having raised a combined total of $63 million in Series A and B rounds. KAI is headquartered in South San Francisco, California.
Partners include: Daiichi Sankyo
Capital

Rounds: 2
Recent Fundings: May 2006   Oct 2004
Capital raised: 63.0M
Last Round: 35.0M
Ownership: Acquired by Amgen (2012 $ 315,000,000 )

Last Tweets


 

Last Mentions


Overview
Record updated: Jan 2017
Sector: Biotech
Headcount: 11-25 as of Mar 2005
Rounds: 2
Recent Fundings: May 2006   Oct 2004
Capital Raised: 63.0M
Last Round: 35.0M
Ownership: Acquired by Amgen (2012 $ 315,000,000 )